Premium
Recombinant human insulin‐like growth factor‐I decreases serum lipoprotein(a) concentrations in normal adult men
Author(s) -
Oscarsson Jan,
Lundstam Ulf,
Gustafsson BJörn,
Wilton Patrick,
Edén Staffan,
Wlklund Olov
Publication year - 1995
Publication title -
clinical endocrinology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.055
H-Index - 147
eISSN - 1365-2265
pISSN - 0300-0664
DOI - 10.1111/j.1365-2265.1995.tb02699.x
Subject(s) - endocrinology , medicine , recombinant dna , insulin , insulin like growth factor , lipoprotein , growth factor , chemistry , cholesterol , receptor , biochemistry , gene
Summary OBJECTIVE Lipoproteln(a) is a lipoprotein fraction associated with atherosclerosis. The serum concentration of llpoprotein(a) has been shown to be mainly genetically determined but recently evidence for hormonal regulation has been presented. The aim of the present study was to Investigate the effects of insulin‐like growth factor‐I on serum lipoproteins, especially lipoprotein(a). DESIGN The effects of one week of IGF‐I treatment were studied in an open trial. SUBJECTS Ten healthy men, who participated In a pharmacokinetic study, were given recombinant human Insulin‐like growth factor‐I (40 μg/kg/day) as daily subcutaneous Injections. MEASUREMENTS Serum samples for measurements of lipoproteins were taken after an overnight fast before and after 7 days of treatment. RESULTS There was a decrease in serum lipoproteln(a) concentration (18.5±5.5%) in nine of the subjects, and a slight increase In one of the subjects with the lowest concentrations. Also serum apolipoprotein (b) (6.3±2.2%), serum cholesterol (10.6±1.8%) and serum triglyceride (14.8±4.8%) concentrations decreased. An unexpected finding was that fasting serum glucose concentrations Increased (13±4%). CONCLUSION Insuiln‐like growth factor‐I is involved in the regulation of lipoprotein(a) concentrations, which might have novel therapeutic Implications.